Researchers from Pritzker Molecular Engineering, under the guidance of Prof. Jeffrey Hubbell, demonstrated that their compound can eliminate the autoimmune response linked to multiple sclerosis. Researchers at the University of Chicago's Pritzker School of Molecular Engineering (PME) have developed

Researchers from Pritzker Molecular Engineering, under the guidance of Prof. Jeffrey Hubbell, demonstrated that their compound can eliminate the autoimmune response linked to multiple sclerosis. Researchers at the University of Chicago’s Pritzker School of Molecular Engineering (PME) have developed

  • @[email protected]English
    6•1 year ago

    Notably they trialled first for coeliac autoimmune, but it’ll be 2024 before phase 2 results are out for that. About 10 years back there was a similar vaccine which also passed phase 1 trials but failed at phase 2. Phase 1 is basically testing that the vaccine does no harm in small groups and it is phase 2 where they measure if it is actually efficacious and to what level. If it passes phase 2, then get your hopes up.

    • @BroccoliFartsEnglish
      2•1 year ago

      I work in clinical (and preclinical) trials. And I have celiac disease. I’m hopeful but not optimistic that I’ll be able to eat pasta within the next decade.